Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the following upcoming investor conferences:
- The Deutsche Bank 40th Annual Health Care Conference being held May 6-7, 2015 at The InterContinental Hotel in Boston, MA. The Company will present on Wednesday, May 6 at 4:50 PM (ET).
- The Bank of America Merrill Lynch 2015 Health Care Conference being held May 12-14, 2015 at the Encore at the Wynn in Las Vegas, NV. The Company will present on Wednesday, May 13 at 11:20 AM (PT).
Executive management will provide an update on DX-2930, KALBITOR® (ecallantide) and the Licensing and Funded Research Portfolio (LFRP).
The presentations will be webcast live and may be accessed by visiting the Investor Relations section of the company’s website at http://investor.dyax.com/events.cfm. The webcasts will also be available on the Dyax website for a limited period of time following the conference.
About Dyax
Dyax is a biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for unmet
medical needs. The Company is developing DX-2930,
a fully human monoclonal antibody, for the prevention of hereditary
angioedema (HAE) attacks. In March 2015, the Company reported positive
safety, pharmacokinetic, biomarker and proof-of-concept efficacy results
from its Phase
1b clinical trial of DX-2930 in HAE patients. Additionally, Dyax
markets KALBITOR®
(ecallantide) for the treatment of acute attacks of HAE in patients
12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax's proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and/or royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking
statements. Statements that are not historical facts are based on Dyax's
current expectations, beliefs, assumptions, estimates, forecasts and
projections about the industry and markets in which Dyax operates. The
statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and assumptions,
which are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed in such forward-looking
statements because of risks, uncertainties and assumptions involved in
any future projections. There are many factors that could cause actual
results to differ from these forward-looking statements, including:
risks and uncertainties relating to the clinical development and
regulatory approval of DX-2930; Dyax's dependence on the expertise,
effort, priorities and contractual obligations of third parties in the
development of DX-2930 and in the marketing, sales and distribution of
KALBITOR; competition from new and existing treatments for HAE; the
uncertainty of patent and intellectual property protection relating to
DX-2930, KALBITOR and the LFRP; Dyax's dependence on licensees and
collaborators for development, clinical trials, manufacturing, sales and
distribution of product candidates in the LFRP; uncertainties as to
whether one or more product candidates in the LFRP will achieve
development and regulatory milestones and be commercialized and generate
royalties; uncertainties regarding Lilly's ability to successfully
market CYRAMZA for the treatment of advanced gastric cancer; and other
risk factors described or referred to in Item 1A, "Risk Factors" in
Dyax's most recent Annual Report on Form 10-K and other periodic reports
filed with the Securities and Exchange Commission. Dyax cautions
investors not to place undue reliance on the forward-looking statements
contained in this release. These statements speak only as of the date of
this release, and Dyax undertakes no obligations to update or revise
these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
CYRAMZA
is a trademark owned by or licensed to Eli Lilly and Company, its
subsidiaries, or affiliates.
Contacts:
Jennifer Robinson, 617-250-5741
Director, Investor
Relations
and Corporate Communications
jrobinson@dyax.com